Navigation Links
'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched
Date:10/21/2011

Paris, France, 21 October 2011 A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.

The PATH B ("Patients and Professionals Acting Together for Hepatitis B") programme was developed by an international advisory board comprising people living with hepatitis B, as well as patient advocacy group representatives and leading hepatologists from across Europe. This programme is provided as an educational service by the World Hepatitis Alliance (WHA) and The European Liver Patients Association (ELPA). The programme was organised and funded by Bristol-Myers Squibb.

The European Association for the Study of the Liver (EASL) also welcomed "the scope of the information the Path B resource provides to patients".

Professor Mark Thursz, Secretary General of the European Association for the Study of the Liver commented: "This resource provides comprehensive and reliable information for patients diagnosed with hepatitis B. I have no doubt that PATH B will help patients to be better informed, empowered and equipped to manage their treatment journey."

The core component of the PATH B programme is a patient-centric resource, PATH B My journey with chronic hepatitis B. This extensive interactive educational resource consists of a hepatitis B journey roadmap that guides patients through every step and aspect of hepatitis B and treatment options. The six stages of the roadmap cover key aspects of a patient's journey with essential information from diagnosis to long-term disease management.

"There is a large information gap for chronic hepatitis B patients between their initial diagnoses and the long-term management of their disease," said PATH B advisory board member, Achim Kautz, ELPA Board Member. "For the first time, this toolkit seeks to fill that unmet need for complete and reliable information that patients can depend on through every step of their disease."

An innovation contained within the PATH B resource is the online diary where patients can record notes, test results, write in medical appointments as well as any disease or treatment related problems they may experience. The resource contains also a 'View Your Progress' tool, which, for the first time, allows patients to plot their test results over time and to chart the progress of their treatment. The aim of this tool is to help patients understand their treatment, therefore aiding adherence.

Charles Gore, President of the World Hepatitis Alliance, praised the resource: "PATH B is the first of its kind in terms of the range of patient materials available in such a portable interactive format. It really does provide practical help for patients."

The PATH B resource was also designed to facilitate better patient-physician dialogue, and to provide trustworthy information.

"As a clinician, I have seen that patients who are more knowledgeable about their disease feel empowered and in control and tend to have better outcomes," said PATH B advisory board member, Dr. Mark Wilkinson of Guy's and St Thomas' Hospital, London, UK.

Although this resource was developed primarily for patients it can also be a helpful tool for physicians to enhance dialogue with patients on disease progression, treatment and the importance of adherence and persistency.

The advisory board members included representatives from the following:


'/>"/>

Contact: Jonathan Falcone
j.falcone@togorun.net
44-207-554-1622
TogoRun
Source:Eurekalert

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. Molecular pathways linked to sex, age affect outcomes in lung cancer
3. Data Strategy Announces SurePath Services Offering for EMC Avamar
4. Defective signaling pathway sheds light on cystic fibrosis
5. Chocolate Industry Leaders Sign Agreement, Align on Path Towards Increasing Consumer Availability & Consistency of Beneficial Cocoa Flavanols
6. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
7. Loyola among worlds top centers in pathology competition
8. TheDigitalPathologyWiki.com A New Resource For Digital Pathology
9. Scott & White Healthcare pathologist is co-investigator on breast cancer study
10. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
11. Dr. Alesia Wagner of U.S. HealthWorks Medical Group Re-elected to Board of Osteopathic Physicians and Surgeons of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: